Dr. Hirayama is an Assistant Professor in the Clinical Research Division at the Fred Hutchinson Cancer Center (Fred Hutch) and in the Division of Hematology and Oncology at the University of Washington, leveraging state-of-the-art technologies in order to gain a comprehensive understanding of the factors impacting outcomes following immunotherapies, such as CD19-targeted chimeric antigen receptor-modified T (CD19 CAR-T) cell therapy. Dr. Hirayama works translating these insights into enhanced therapeutic approaches, ultimately leading to improved patient outcomes.